Kornimate/medical-research-clean huggingface dataset:
sorafenib and bevacizumab in combination with paclitaxel in patients with solid tumors

Conditions: SOLID TUMORS

Summary: the purpose of this study is to evaluate the safety and tolerability and describe the maximum tolerated dose (mtd) of treatment with escalating doses of sorafenib in combination with bevacizumab and paclitaxel for patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * histological or cytological diagnosis of a solid tumor with evidence of residual, recurrent, or metastatic disease. patients must be incurable by surgical or other standard available therapy * measurable or evaluable disease; tumor size of ≥ 2 cm on ct scan * patients may have received prior standard taxane therapy or anti-vegf therapy, but may not have progressed on both therapies. progression on one type therapy (either taxane or anti-vegf) is allowed exclusion criteria: * history or presence of central nervous system (cns) disease (i.e., primary brain tumor, malignant seizures, cns metastases or carcinomatous meningitis). * prior chemotherapy ≤ 3 weeks prior to registration. patients must have recovered from all therapy-related toxicities * prior biologic or immunotherapy ≤ 3 weeks prior to registration. patients must have recovered from all therapy-related toxicities * prior full pelvic field radiotherapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks prior to randomization. patients must have recovered to less than or equal to grade 1 from all therapy-related toxicities except alopecia. the site of previous radiotherapy should have evidence of progressive disease if this is the only site of evaluable disease * major surgery (i.e., laparotomy) ≤ 4 weeks prior to randomization or anticipation of need for major surgical procedure during the course of the study * minor surgery ≤ 2 weeks prior to randomization. insertion of a vascular access device is not considered major or minor surgery in this regard. patients must have recovered from all surgery-related toxicities * peripheral neuropathy with functional impairment ≥ common terminology criteria (ctc) grade 2 neuropathy, regardless of causality * pleural effusion or ascites that causes respiratory compromise (≥ ctc grade 2 dyspnea) * concurrent severe and/or uncontrolled cardiac, vascular or infectious conditions (as described in the protocol) which could compromise participation in the study * patients at risk of qt prolongation such as patients with congenital long qt syndrome or with long corrected qt (qtc) at baseline (i.e. qtc greater than 450 msec in males, and greater than 470 msec in females) will be excluded * lung carcinoma of squamous cell histology (mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible; sputum cytology alone is not acceptable).

Keywords: solid tumor
assessing demographic biases in deep learning model for fetal growth estimation in clinical practice. patients eligible for inclusion are women with a gestational age between 24-42 weeks undergoing a third-trimester growth scan. the image data from the scan are used to calculate fetal weight.

Conditions: Pregnancy Complications

Summary: the goal of this observational study is to compare a new artificial intelligence (ai) feedback tool with the traditional method for estimating fetal weight during ultrasound scans on pregnant women between 24-42 weeks of gestation. the study aims to investigate the presence of demographic bias in the ai model. the demographic factors examined in the study include body mass index (bmi), the number of births, fetal age, mother\&#39;s age, fetal sex, and the presence of preeclampsia. moreover, the study will compare the accuracy of the ai model and the hadlock model, a fetal growth formula, in estimating fetal weight. participants will have their ultrasound scans pseudonymized and securely stored on password-protected removable drives, ensuring their identity and privacy are maintained. afterward, the ultrasound data will be sent to the technical university of denmark (dtu), where the ai model will analyze the images to estimate fetal weight.


Eligibility criteria:
inclusion criteria: * women with gestational age between 24-42 weeks undergoing a third-trimester growth scan. exclusion criteria: * women with multiple pregnancies.
evaluation of cognitive and physical training on mci elders

Conditions: Cognitive Impairment; Mild Cognitive Impairment

Summary: this study examines the impact of combining cognitive and physical training, recognizing that daily living often requires individuals to perform multiple tasks simultaneously. the inability to execute such dual movements can hinder daily functioning. the primary goal is to enhance the ability of individuals with mild cognitive impairment (mci) to perform two tasks concurrently, focusing on both cognitive and physical aspects. this research aims to deepen our understanding of how multitasking affects patients' abilities and to develop effective intervention programs.

the world health organization has recognized cognitive impairment as a significant global health issue, encompassing a spectrum of conditions from mild cognitive impairment to various forms of dementia. these conditions are linked to heightened risks of disability and mortality. in the absence of suitable interventions, cognitive functions typically exhibit a gradual decline over time, driven by factors including aging, neurological disorders, traumatic brain injury, and substance abuse. a thorough literature review indicates that cognitive and physical training can sustain cognitive or physical functions, contingent upon the specific training protocols implemented. concurrent cognitive and physical training entails the simultaneous execution of multiple cognitive and motor activities, thereby maintaining dual functional control. this innovative training modality integrates motor and cognitive rehabilitation into a cohesive framework. this clinical trial adopts a randomized controlled design, stratifying participants into four distinct groups: cognitive training, physical training, combined cognitive and physical training, and passive informational activities. the interventions will be administered with a frequency of three times per week over a 12-week period, incorporating task-specific training to enhance both motor and cognitive functions.

Eligibility criteria:
inclusion criteria: 1. participants must be aged 60 years or older and able to communicate in mandarin or taiwanese. 2. mild cognitive impairment, assessed using the mini mental state examination (mmse) with a score of 14≦mmse≦25. 3. self-reported complaints of cognitive decline. 4. in addition to the above criteria, participants must voluntarily agree to participate and sign an informed consent form. exclusion criteria: 1. individuals with severe psychiatric disorders or behavioral problems, as assessed by the neuropsychiatric inventory questionnaire (npi-q) with (a) severity score ≥ 6 and caregiver distress score ≥ 7. 2. participants who have undergone other cognitive or activity training within the past six months. 3. individuals with sensory impairments, such as visual, auditory, or communication difficulties. 4. people with mobility impairments, such as those who use wheelchairs or mobility aids.
a comparison of ly2963016 to a basal insulin after a single dose in healthy subjects

Conditions: Diabetes Mellitus

Summary: the purposes of this study are to determine the pharmacokinetics and pharmacodynamics of ly2963016 compared to those of basal insulin. the study will also gather information on the safety and tolerability of ly2963016 in healthy subjects. the study is approximately 12 weeks.


Eligibility criteria:
inclusion criteria: * are overtly healthy males or females * have a body mass index (bmi) between 18.5 and 29.9 kilogram per square meter (kg/m\^2) * are nonsmokers * have normal blood pressure and pulse rate * have an electrocardiogram (ecg) considered as within normal limits * have clinical laboratory test results within normal reference range exclusion criteria: * are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device * have known allergies to insulin or its excipients * have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders * show evidence of significant active neuropsychiatric disease * have a history of first-degree relatives known to have diabetes mellitus * have a fasting venous blood glucose \>6.0 millimoles per liter (mmol/l) * intend to use over-the-counter or prescription medication * have donated or had a blood loss of 450 milliliters (ml) or more in the past 3 months * have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females)
thrive improves early postoperative atelectasis in long-time non-tracheal intubation anesthesia for gastrointestinal endoscopy: a clinical study

Conditions: Early Postoperative Atelectasis

Summary: this study aims to explore the clinical effect of thrive in improving early postoperative atelectasis in patients undergoing long-term non-intubated anesthesia gastrointestinal endoscopy.


Eligibility criteria:
inclusion criteria: 1. multiple polyps resection, esd(endoscopic submucosal dissection) , emr(endoscopic mucosal resection), enteroscopy and other gastrointestinal endoscopic diagnosis and treatment were performed 2. the duration of anesthesia is more than 30 minutes, that is, from induction to withdrawal of anesthesia 3. asa(american society of anesthesiologists) ≤ ii 4.18kg/m2\<bmi\<30 kg/m2 5.informed consent, voluntary participation in the experiment, and signed by the subject informed consent exclusion criteria: 1. asa classification ≥ iii; 2. history of previous lung or nasal surgery; 3. history of chronic obstructive pulmonary disease (copd) or restrictive lung disease; 4. history of obstructive sleep apnea syndrome; 5. history of upper airway obstruction; 6. history of head and neck radiation therapy; 7. significant nasal septum deviation; 8. active infection (defined as a white blood cell count \>10\*10\^9 or a body temperature \>38°c); 9. gastrointestinal perforation; 10. combined use of other anesthetic methods or inhalation anesthetics outside of non-intubated intravenous anesthesia; 11. concurrent other medical procedures besides the prescribed gastrointestinal endoscopic procedures, such as ercp(endoscopic retrograde cholangiopancreatography); 12. severe communication disorders due to conditions like severe hearing impairment or dementia; 13. disagreement with participation in the study.
the effect of a nutritional supplement product containing cactus fruit juice (nopalea) on c-reactive protein

Conditions: Inflammation

Summary: this study has been developed to investigate the anti-inflammatory effects of a commercial product (nopalea) containing prickly pear cactus fruit juice in healthy adults. the research method employs a double blind, placebo controlled, and time-series (repeat measures) design with high-sensitivity c-reactive protein (hs-crp) serving as a marker for inflammation - testing for levels of crp at time points: baseline (pre-test), 8 weeks (60 days) and 12 weeks (90 days). the final time point (i.e., 12 weeks) will serve as the post-test. it is expected that baseline crp levels in healthy participants will decline.


Eligibility criteria:
live within traveling distance of the research center. access to a telephone in their residence. between 35 and 75 years of age not currently ingesting nopalea not pregnant, planning to become pregnant, or nursing a child not currently taking anti-inflammatory medications medically stable - i.e. no recent major change in the last 3 weeks of prescription or non- prescription medication not diagnosed with type 1 diabetes not diagnosed with depression not diagnosed with an acquired or congenital immune system deficiency

Keywords: crp nopalea fruit juice
observational study of patients with advanced melanoma (skin cancer) to assess if iopener®-melanoma test can predict response to immunotherapy.

Conditions: Melanoma Metastatic; Melanoma, Skin; Melanoma Stage III or IV; Melanoma Advanced

Summary: the goal of this observational study is to assess whether the iopener® melanoma test can assist treating physicians in deciding which therapy is most suitable for patients with skin cancer (advanced cutaneous melanoma). for this purpose it is evaluated how well the iopener-melanoma test can predict the result of cancer treatment in the treatment groups (standard of care anti-pd1 mono-therapy and standard of care anti-pd1 + anti-ctla-4 therapy). participants will be asked to provide blood sample for analysis using iopener®-melanoma test. patients will receive regular medical care, the test results will not be used to make any treatment decisions. the patients will visit the clinic for treatment administration and clinical evaluation as part of their regular medical care.


Eligibility criteria:
inclusion criteria: * first line treatment for unresectable stage iii or iv cutaneous melanoma (according to ajcc version 8) with anti-pd1 monotherapy (nivolumab or pembrolizumab) or anti-pd1 + anti-ctl4a combination therapy (nivolumab and ipilimumab). * anticipated life expectancy exceeding 3 months. * aged 18 years or older and able to provide written informed consent. patients who have completed adjuvant treatment with anti-pd1 immunotherapy at least 6 months ago can be included. exclusion criteria: * prior treatment for irresectable stage iii or stage iv melanoma with braf/mek inhibitors. * presence of progressive/symptomatic brain metastases at baseline. * who performance score ≥ 2. * adjuvant treatment with anti-pd1 immunotherapy received within the last 6 months. * patients undergoing experimental treatments or therapies. * presence of any medical or other condition that in the opinion of the investigator(s) would preclude the participation in a clinical study. * unwillingness or inability to comply with study and follow-up procedures.

Keywords: melanoma iopener immunotherapy immune checkpoint inhibitor
measurement of alanine aminotransaminase (alt) following initiation of antidiabetic agents in patients with type 2 diabetes in a real-world clinical setting: a retrospective cohort study

Conditions: T2DM (Type 2 Diabetes Mellitus); Fatty Liver; NAFLD

Summary: the primary objective of this study is to investigate the change in alanine aminotransaminase (alt) in patients with type 2 diabetes mellitus (t2dm) initiating sodium glucose cotransporter 2 (sglt2) inhibitors, liraglutide, or sitagliptin, compared to a control group of patients who did not initiate a new antihyperglycemic therapy. the hypothesis is that patients using sodium glucose cotransporter 2 inhibitors (sglt2i) will achieve a greater reduction in alt compared to the control group.

non-alcoholic fatty liver disease (nafld) is very commonly associated with type 2 diabetes mellitus (t2dm) 1. alanine aminotransferase (alt) is a common biomarker used to predict levels of nafld. the only class of antidiabetic agents thought to be protective of nafld are thiazolidinedione's. few studies have investigated the effect of other antidiabetic agents on bio markers of fatty liver disease 2. a recent pooled analysis of randomized controlled trials that compared canagliflozin to either placebo or sitagliptin showed significant reductions in alt in the canagliflozin cohorts, which were fully explained by hba1c and body weight reductions 3. as well, a study that compared alt change in patients initiating liraglutide found significant reductions in alt, which was strongly correlated to reduction in body weight 4. however, the effect of different antidiabetic agents on bio markers of fatty liver disease is not well characterized. the primary objective of this study is to investigate the change in alt in patients with t2dm initiating sglt2 inhibitors, liraglutide, or sitagliptin, compared to a control group of patients who did not initiate a new antihyperglycemic therapy. the hypothesis is that patients using sglt2i will achieve a greater reduction in alt compared to the control group.

Eligibility criteria:
inclusion criteria: * diagnosis of t2dm based upon historical clinical diagnosis * patients who initiated canagliflozin, dapagliflozin, liraglutide or sitagliptin by an lmc physician between january 2011 and december 2015, or patients who did not initiate a new diabetes therapy between june 2014 and june 2015. exclusion criteria: * diagnosis of type 1 diabetes * patients who switched to one of the study treatments from another medication of the same medication class
iron sucrose versus ferrous bis-glycinate for treatment of iron deficiency anemia

Conditions: Anemia

Summary: iron deficiency may result from inadequate dietary intake, achlorhydria or excessive ingestion of proton pump inhibitors, parasitic infestations, chronic infections and repeated pregnancies. iron supplementation of antenatal patients is a basic tenet of antenatal care programmes in numerous developing and underdeveloped nations. postpartum anemia is defined as hemoglobin of less than 11.5 gm% during the postpartum period. the prevalence of postpartum anemia varies from 4 - 27%. chronic iron deficiency due to inadequate intake/ lack of iron supplementation during pregnancy, repeated pregnancies and postpartum hemorrhage are important causes of postpartum anemia


Eligibility criteria:
inclusion criteria: hemoglobin level 7-11.5 gm/dl. no chronic diseases. breastfeeding. delivered at gestational age \>38 weeks. within 24-72 hours postpartum. women who accept to participate in the study exclusion criteria: 1. severe anemia \< 7 gm/dl. 2. women received iron therapy during pregnancy. 3. intolerance to iron preparations 4. anemia due to other causes 5. peripartum blood transfusion.
combining non-invasive brain stimulation and exercise to treat low back pain

Conditions: Chronic Low-back Pain

Summary: the aim of this study is to evaluate the efficacy of repetitive transcranial magnetic stimulation alone and in combination with motor control exercises on pain and disability for patients with chronic non-specific low back pain.


Eligibility criteria:
inclusion criteria: * chronic low back pain, defined as "pain in the low back area with or without leg pain above the knee limiting activities or daily routine which has been present for more than 3 months"; * a minimal average pain intensity of 3 out of 10 during the preceding week on a pain numerical rating scale; * a minimal score of 10 points on the oswestry disability index (odi). exclusion criteria: * specific spinal pathology (fracture, tumor, radiculopathy, spinal infection, etc.); * a history of back surgery; * a major orthopedic, neurological, cardiovascular or psychiatric illness; * low back pain is not the main pain complaint; * currently using an exercise program to treat their lbp; * presenting with any specific tms/rtms-related exclusion criteria such as previous seizure/convulsion, cochlear implant, specific medication and pregnancy; * previous use of repetitive transcranial magnetic stimulation.

Keywords: transcranial magnetic stimulation motor control exercises randomized controlled trial
treatment of head lice infestation using novel ultrasonic comb

Conditions: Pediculus Capitis

Summary: a pilot study to evaluate safety and efficacy of the lucy combined with lucygel in killing head lice and their eggs. 23 participants will be enrolled in this study. the first 12 will be combed with model a and the remaining 11 will be combed with model b


Eligibility criteria:
inclusion criteria: * males and females * age 6 years and older at the time of enrollment * must have an active head lice infestation of at least 10live head lice (found within 5 minutes of mechanic search). * hair must be at least 3 cm long. * written informed consent - by patient (if over 18 years of age), or by a parent (if patient is under 18 years of age). * for females of childbearing potential, a statement declaring that she is not currently pregnant. exclusion criteria: * used any chemical head lice treatment in the 7 days preceding the trial treatment * used antibiotics in the week preceding treatment * open wounds in the treatment area * skin irritation in the treatment area * individuals with skin/scalp condition at the treatment site which, in the opinion of the investigator, will interfere with treatment or evaluation * known allergies to any of the gel's components * participant that is already enrolled in another study * participant who can't be combed with fine comb dense assy2000
impact of microbial exposure of the habitat at the time of birth on the development of allergic diseases.

Conditions: Allergic Disorder

Summary: in 2001-2002, a longitudinal study on the risk of atopic sensitization in children was conducted by the pneumo-allergology and pediatrics departments of the chu saint-pierre hospital and at the neonatology department of the queen fabiola children's university hospital (huderf). the aim of the study was to study bacteria and endotoxins in airborne dust in brussels homes in order to evaluate their impact on the development of allergic diseases in newborns. between december 2000 and august 2002, 114 children (67 from huderf and 47 from chu st-pierre) were included in the study. these were eutrophic children without acquired pathology or known genetics. simultaneously a microbial habitat assessment was performed based on a detailed description and on endotoxin assays in the airborne and deposited dust (mainly mattress).these data can be used to define habitats with high or low contamination.samples for microbial analyzes (gram positive and negative and mold) were also carried out. preliminary results suggested: 1. a protective effect of airborne dust endotoxins on the risk of developing atopic dermatitis in children at 6 and 12 months of life, 2. an effect of endotoxins promoting the occurrence of wheezing in children after 6 months. in this current, new study, the investigators will recontact the children who were included in the 2003 study. the goal is to evaluate them clinically and allergically and associate the risk of sensitization / allergic diseases with the microbial exposure of the habitat, measured during the neonatal period. siblings and parents who were exposed during the same period will also be evaluated.


Eligibility criteria:
inclusion criteria: children who participated in the study conducted in 2001-2002, their parents and the siblings who were exposed to the same environment at this period. exclusion criteria: none
axitinib (ag-013736) with or without dose titration (increase) in patients with kidney cancer

Conditions: Carcinoma, Renal Cell

Summary: axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.


Eligibility criteria:
inclusion criteria: * metastatic renal cell carcinoma (kidney cancer) with clear cell component * no prior systemic therapy (including no prior adjuvant or neoadjuvant) * eastern cooperative oncology group (ecog) performance status 0-1 * blood pressure \< or = 140/90mmhg exclusion criteria: * brain/cns metastasis * using more than 2 blood pressure medications

Keywords: axitinib or ag-013736 dose titration (increase) renal cell carcinoma kidney cancer